cp wire

CP Wire Articles

CymaBay Announces Positive Efficacy and Safety Results from its Ongoing Phase 2 Study of Seladelpar in Patients with Primary Biliary Cholangitis

  • Seladelpar maintains potent anti-cholestatic and anti-inflammatory activity and appears safe and well tolerated, with no drug-induced pruritus, through 26 weeks of treatment
    • ... read more
Wed, 04/11/18 - 11:18 am
Fujifilm Kyowa Kirin Biologics Partners with Mylan to Commercialize Biosimilar to Humira in Europe

Fujifilm Kyowa Kirin Biologics Co., Ltd. today announced the company will partner with Mylan N.V. (NASDAQ:MYL) to commercialize FKB327, a biosimilar to Humira (adalimumab) developed by Fujifilm... read more

Wed, 04/11/18 - 09:32 am
Nektar begins Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 With CD122-Biased Agonist NKTR-214 in Patients With Advanced Solid Tumors

Nektar Therapeutics (Nasdaq: NKTR) today announced that it has initiated dosing patients in the Phase 1/2 REVEAL clinical study evaluating the efficacy and safety of the combination of... read more

Wed, 04/11/18 - 09:18 am
Quadrant Biosciences Enters into Licensing Agreements for Commercialization of Novel Epigenetic Biomarkers to Detect Autism, Parkinson's, and Concussion

Quadrant Biosciences announced today the execution of three licensing agreements with SUNY Upstate Medical University and Penn State University for the global commercialization of epigenetic... read more

Tue, 04/10/18 - 10:03 pm
Pfizer Announces Failure of Phase 3 Trial of Axitinib as Adjuvant Treatment for Patients at High Risk of Renal Cell Carcinoma Recurrence After Surgery

Pfizer announced today that the independent Data Monitoring Committee for the Phase 3 ATLAS trial evaluating Inlyta The study failing to demonstrate a clear improvement in the primary endpoint of... read more

Tue, 04/10/18 - 02:44 pm

Pages